Research programme: transmucosal nausea and vomiting therapy - Meldex

Drug Profile

Research programme: transmucosal nausea and vomiting therapy - Meldex

Alternative Names: DBP 118

Latest Information Update: 03 Jun 2008

Price : $50

At a glance

  • Originator BioProgress
  • Developer BioProgress Technology Ltd; ULURU
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Nausea and vomiting

Most Recent Events

  • 03 Jun 2008 Preclinical development is ongoing
  • 04 May 2006 Preclinical trials in Nausea and vomiting in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top